Zacks Investment Research on MSN1d
How to Play SRPT Stock After Patient Death Post DMD Therapy Infusion
Shares of Sarepta Therapeutics SRPT plunged nearly 24% last week after the company reported the death of a patient following ...
News80003d
Boy is first American to receive groundbreaking treatment for muscular dystrophy
An 8-year-old northern Minnesota boy is one of the first in the country to receive a specific type of gene therapy treatment.
Study explores restoring heart function in myotonic dystrophy type 1
Myotonic dystrophy type 1 (DM1) is the most common adult-onset form of muscular dystrophy and a condition that severely ...
The American Journal of Managed Care6d
Exploring Care Needs, Physical Activity in Myotonic Dystrophy
1-2 Recent studies presented at the 2025 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference shed light on these issues. Because myotonic dystrophy type 1 is a rare, progressive ...
The American Journal of Managed Care7d
How Access to SMA Treatment Varies Globally and by Insurance Type
Posters presented at the 2025 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference show that therapeutic ...
Dyne Therapeutics' $4.3 Billion Peak Sales Potential? Analyst Highlights Key Strengths And Risks
BMO Capital Markets initiated coverage on Dyne Therapeutics, Inc. (NASDAQ:DYN), focused on developing therapies for ...